Prostate Cancer Dormancy and Reactivation in Bone Marrow
Deepak K Singh1, Vaibhav G Patel2, William K Oh2
1Division of Hematology and Oncology, Department of Medicine, Department of Otolaryngology, Department of Oncological Sciences, Tisch Cancer Institute, Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Journal of Clinical Medicine
|July 2, 2021
Summary
Targeting early prostate cancer cells, known as disseminated cancer cells (DCCs), is crucial. Understanding their dormancy and activation in bone marrow offers new therapeutic strategies against metastatic spread.
Area of Science:
- Oncology
- Cancer Biology
- Cellular Metastasis
Background:
- Prostate cancer exhibits diverse clinical trajectories, from localized to metastatic disease.
- Eradicating established metastatic prostate cancer cells remains a significant therapeutic challenge.
- Disseminated cancer cells (DCCs) migrate early and can lie dormant before forming metastases.
Purpose of the Study:
- To explore the biology of disseminated cancer cells (DCCs) in prostate cancer.
- To understand the mechanisms governing DCC dormancy and activation.
- To identify potential therapeutic targets for early-stage prostate cancer metastasis.
Main Methods:
- Review of recent discoveries in dormancy signaling.
- Analysis of the tumor microenvironment's (TME) role in epigenetic reprogramming of DCCs.
- Exploration of interactions between DCCs and primary/secondary niches.
Main Results:
- Bone marrow is a primary site for prostate cancer DCC dormancy and subsequent metastasis.
- The interplay between DCCs and their microenvironment dictates dormancy-activation transitions.
- Epigenetic reprogramming by the TME influences DCC fate.
Conclusions:
- Targeting DCCs during earlier disease states presents a critical therapeutic window.
- Understanding dormancy signaling and TME interactions is key to developing novel prostate cancer therapies.
- Strategies to target DCCs hold promise for preventing or treating metastatic prostate cancer.
Related Concept Videos
02:40Cancer Stem Cells and Tumor Maintenance
5.2K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.2K
01:19Multipotency of Hematopoietic Stem Cells
3.5K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.5K
01:22Bone Marrow Sampling and Transplants
599
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
599